While the call for legalizing marijuana is achieving widespread support in many states of America, the legislative committee has set back over the marijuana reform on Tuesday, by rejecting the regulation which will support the medical marijuana industry, creating disappointments among many. The regulation would have changed the designation of marijuana among the psychotropic drugs as a Schedule I drug to a Schedule II drug, in turn easing the statutory restrictions on using and producing it.
Schedule I drugs are highly addictive without any medical uses, however Schedule II drugs have medical benefits and are allowed under the Federal Drug Act enacted in 1970. Many states are now amending their policies in accordance with the growing support for marijuana legalization, even while the federal laws are remaining strict. However, according to reports, authorities are saying that it is not a setback over people’s interests, but the legislative committee is taking more time to look at the medical marijuana regulations in their entirety.
The Commissioner of the state Department of Consumer Protection, who is drawing up the rules and regulations for growing and distributing marijuana for clinical purposes, commented that the rejection of the proposal is meant for careful appraisal but not a setback for the program.
“Members on the committee would like to see both sets of regulations at the same time,” says co-chairman of the Regulation Review Committee. The proposed regulations have been put to vote after a lengthy discussion on the use of marijuana in medical fields.
“Folks on the committee still have issues. Instead of piecemealing the regulations, we would like to maybe see them in a package, so that we can look at how we are changing from Schedule I to Schedule II and then, obviously, the dispensing of it. We want to make sure we have our finger on how it’s going to roll out in the state of Connecticut,” he added.
Political interest has gone high on the issue, and even the GOP is ready to amend its stand on the classical liberalization concepts, favoring the majority’s interest. According to reports, the issue is expected to return to the committee this summer and a state regulatory system will be coming to supervise marijuana trade and use.